ONE 03/15 19:30 Actelion Pharmaceuticals Ltd: Selexipag (Uptravi) long-term outcome data in pulmonary arterial hypertension presented at Americ
BN 03/15 19:37 *ACTELION SAYS DRUG SIGNIFICANTLY INCREASED 6-MIN. WALK DISTANCE
BN 03/15 19:32 *ACTELION'S SELEXIPAG IMPROVED LONG-TERM OUTCOMES
BN 03/15 19:31 *ACTELION SELEXIPAG SIG. CUT MORBIDITY RISK 40% VS PLACEBO
BN 03/15 19:37 *ACTELION SAYS DRUG SIGNIFICANTLY INCREASED 6-MIN. WALK DISTANCE
BN 03/15 19:32 *ACTELION'S SELEXIPAG IMPROVED LONG-TERM OUTCOMES
BN 03/15 19:31 *ACTELION SELEXIPAG SIG. CUT MORBIDITY RISK 40% VS PLACEBO
Actelion’s Selexipag Cut Morbidity Risk 40% vs Placebo
2015-03-15 19:51:04.209 GMT
By Dan Hart
(Bloomberg) -- Selexipag improved L-T outcomes in patients
w/pulmonary arterial hypertension, drugmaker says in statement.
Co. presented data at American College of Cardiology meeting in
San Diego.
* Drug “significantly reduced” risk of morbidity/mortality
event (p<0.0001), company said
* Actelion says drug led to “significant increase” in six-
minute walk distance at wk 26 w/12 meters in entire patient
population (p=0.0027), and 34 meters for PAH-treatment-naive
patients (p=0.0002)
* Proportion of patients discontinuing treatment because of
adverse events was 14% on selexipag and 7% on placebo
Link to Statement:Link
Link to Company News:{ATLN VX <Equity> CN <GO>}
For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}
To contact the reporter on this story:
Dan Hart in Washington at +1-202-624-1870 or
dahart@bloomberg.net
To contact the editor responsible for this story:
Sylvia Wier at +1-212-617-8958 or
swier@bloomberg.net
2015-03-15 19:51:04.209 GMT
By Dan Hart
(Bloomberg) -- Selexipag improved L-T outcomes in patients
w/pulmonary arterial hypertension, drugmaker says in statement.
Co. presented data at American College of Cardiology meeting in
San Diego.
* Drug “significantly reduced” risk of morbidity/mortality
event (p<0.0001), company said
* Actelion says drug led to “significant increase” in six-
minute walk distance at wk 26 w/12 meters in entire patient
population (p=0.0027), and 34 meters for PAH-treatment-naive
patients (p=0.0002)
* Proportion of patients discontinuing treatment because of
adverse events was 14% on selexipag and 7% on placebo
Link to Statement:Link
Link to Company News:{ATLN VX <Equity> CN <GO>}
For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}
To contact the reporter on this story:
Dan Hart in Washington at +1-202-624-1870 or
dahart@bloomberg.net
To contact the editor responsible for this story:
Sylvia Wier at +1-212-617-8958 or
swier@bloomberg.net